H2 & H3 Antagonist
| Home | | Pharmacology |Chapter: Essential pharmacology : Histamine And Antihistaminics
The first H2 blocker Burimamide was developed by Black in 1972. Metiamide was the next, but both were not found suitable for clinical use. Cimetidine was introduced in 1977 and gained wide usage. Ranitidine, famotidine, roxatidine, and many others have been added subsequently.
H2 ANTAGONIST
The first H2 blocker Burimamide was developed by Black
in 1972. Metiamide was the next, but
both were not found suitable for clinical use. Cimetidine was introduced in 1977 and gained wide usage. Ranitidine, famotidine, roxatidine, and many others have been
added subsequently. They are
primarily used in peptic ulcer and other gastric hypersecretory states.
H3 ANTAGONIST
Though a selective H3 antagonist thioperamide has been
produced, it has not found any clinical utility.
Related Topics
